Myelodysplastic Syndrome News

News

CPX-351 vs FLAG-Ida Treatment for Patients With Adverse Karyotype AML/High-Risk MDS

09/29/2023

Gina Tomaine

The overall survival of younger patients with adverse risk AML/MDS was not significantly different between treatment with CPX-351 or FLAG-Ida, according to findings from the UK NCRI AML19 trial.

The overall survival of younger...

09/29/2023

Oncology

News

Triplet Combination Yields Encouraging Activity for Newly Diagnosed Secondary AML, MDS, or CMML After Failure of Hypomethylating Agents

09/27/2023

Jordan Kadish

The combination of azacitidine, venetoclax, and pevonedistat yielded encouraging efficacy among a poor-risk population of patients with AML, MDS or CMML, according to a phase 1/2 trial.

The combination of azacitidine,...

09/27/2023

Oncology

News

Eltrombopag Demonstrated Efficacy, Relative Safety Among Patients With Low-Risk MDS and Severe Thrombocytopenia

09/20/2023

Jordan Kadish

Eltrombopag demonstrated efficacy and relative safety among patients with low-risk myelodysplastic syndromes and severe thrombocytopenia, according to the phase 2 EQOL-MDS trial.

Eltrombopag demonstrated...

09/20/2023

Oncology

News

Evaluating Long-Term Clinical Efficacy of ESAs Among Patients With Low‑Risk or Intermediate‑1‑Risk MDS

09/11/2023

Gina Tomaine

Erythropoiesis‑stimulating agent efficacy began to plateau after the 24th month of therapy among patients with low‑risk or intermediate‑1‑risk MDS, followed by a decrease in response rates, according to data presented at the SOHO 2023 annual...

Erythropoiesis‑stimulating agent...

09/11/2023

Oncology

News

Analysis of Real-World Outcomes in First-Line Treatment Among Patients With Myelodysplastic Syndromes

09/08/2023

Gina Tomaine

Improved first-line clinical strategy for treating patients with lower-risk MDS would be beneficial, according to a global, retrospective study presented at the Society of Hematologic Oncology 2023 Annual Meeting.

Improved first-line clinical...

09/08/2023

Oncology

News

Transfusion Burden Decrease, Hemoglobin Increase With Luspatercept vs Epoetin Alfa Treatment for ESA‑Naive Patients With Transfusion‑Dependent Lower‑Risk MDS

09/08/2023

Gina Tomaine

Luspatercept demonstrated multiple clinical benefits for ESA-naive patients with transfusion-dependent lower-risk MDS, including hemoglobin increases and transfusion-burden decreases, according to research presented at the SOHO 2023 Annual...

Luspatercept demonstrated...

09/08/2023

Oncology

News

G-CSF Plus Decitabine and Busulfan-Cyclophosphamide Conditioning for Patients With MDS-RAEB and Secondary AML Evolving From MDS

05/11/2023

Jordan Kadish

According to a phase 3 trial, a granulocyte-colony stimulating factor plus decitabine and busulfan-cyclophosphamide conditioning regimen reduced the incidence of relapse among patients with MDS refractory anemia with excess blasts and...

According to a phase 3 trial, a...

05/11/2023

Oncology

News

Magrolimab and Azacitidine Combination Treatment for Patients With Untreated High-Risk MDS

04/28/2023

Jordan Kadish

According to a phase 1b trial, magrolimab and azacitidine combination treatment yielded safe and effective results among patients with untreated high-risk myelodysplastic syndromes.

According to a phase 1b trial,...

04/28/2023

Oncology

News

Combination of CCAG Regimen and Donor Lymphocyte Infusion Induced Durable Remission and Superior Survival Among Patients With Relapsed AML/MDS

02/27/2023

Jordan Kadish

A single-arm phase 2 study found that a combination of chidamine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor followed by donor lymphocyte infusion induced durable remission and superior survival in patients with...

A single-arm phase 2 study found...

02/27/2023

Oncology

News

Post-Transplant Eprenetapopt Plus Azacitidine Maintenance Shows Promise in TP53-Mutant AML and MDS

08/18/2022

Gina Tomaine

Findings from a phase 2 study show post-transplant maintenance therapy with eprenetapopt plus azacitidine has the potential to improve outcomes for patients with TP53-mutant AML and MDS.

Findings from a phase 2 study...

08/18/2022

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology